Antibiotic resistance. Epidemiology of resistance in intensive therapy units (ITUs).
Fraise
A P
AP
Hospital Infection Research Laboratory, City Hospital, Birmingham, UK.
D042462:4-Quinolones; D000150:Acinetobacter / Q000187:drug effects; D000151:Acinetobacter Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D004352:Drug Resistance, Microbial / Q000235:genetics; D016983:Enterococcus / Q000187:drug effects*; D004790:Enzyme Induction / Q000235:genetics; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000201:enzymology / Q000235:genetics; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units; D016106:Methicillin Resistance; D009154:Mutation; D015995:Prevalence; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D006113:United Kingdom / Q000453:epidemiology; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use; D001618:beta-Lactamases / Q000096:biosynthesis / Q000235:genetics
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D014640:Vancomycin; D001618:beta-Lactamases